ReviewNature reviews. Microbiology2008
Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria.
Review in Nature reviews. Microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 240 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
240 citing papers in PubMed, 538 citations in OpenAlex.
- Article
- Oral immunization with recombinant Lactococcus lactis expressing VP3 and VP3-IFNα fusion protein protects ducklings against novel goose parvovirus infection.Poultry science · 2026Article
- Overcoming Antigenic Drift in PEDV: Broadly Protective Antigen Design and sIgA-Driven Lactogenic Immunity.Veterinary sciences · 2026Review
- Charge-Competition AIEgens Induce Mitochondrial Dysfunction for Selective Eradication ofJournal of microbiology and biotechnology · 2026Article
- A standardized toolkit for programmable protein secretion and surface display inbioRxiv : the preprint server for biology · 2026Article
- Navigating a thorny path: oral nanomedicines for the precision management of radiation-induced intestinal injury.Journal of nanobiotechnology · 2026Review
- Genetically Modified Lactic Acid Bacteria: a Promising Mucosal Delivery Vector for Vaccines.Probiotics and antimicrobial proteins · 2026Review
- IFITM3-expressing Lactobacillus plantarum (HA-r-LAB) as a probiotic vector for targeted immunotherapy against TGEV.Veterinary research · 2025Article
- Construction of genetically modified lactic acid bacteria producing an Anti-Interleukin-31 receptor A Single-chain variable fragment.Molecular biology reports · 2025Article
- Mitigating Virulence of Environmental Enterococcus faecalis Via Fermented Food-Derived Lactic Acid Bacteria.Current microbiology · 2025Article
- Transcriptomic Analysis of Immune Tolerance Induction in NOD Mice Following Oral Vaccination with GAD65-Vaccines · 2025Article
- Harnessing flagellin ofApplied and environmental microbiology · 2025Article
- Intranasal Drug Delivery Technology in the Treatment of Central Nervous System Diseases: Challenges, Advances, and Future Research Directions.Pharmaceutics · 2025Review
- Highlighting Lactic Acid Bacteria in Beverages: Diversity, Fermentation, Challenges, and Future Perspectives.Foods (Basel, Switzerland) · 2025Review
- A Nasal Vaccine Displaying Anthrax Antigen on the Surface ofJournal of microbiology and biotechnology · 2025Article
- Utilization of Native CRISPR-Cas9 System for Expression of Glucagon-like Peptide-1 inFoods (Basel, Switzerland) · 2025Article
- Oral and parenteral vaccination of broiler chickens with Recombinant NetB antigen from Clostridium perfringens confers significant protection against necrotic enteritis.BMC veterinary research · 2025Article
- Surface display of two neoantigens on Lactiplantibacillus plantarum.Scientific reports · 2025Article
- Article
- Design of Mucosal Vaccines Against Swine Enteric Coronaviruses: From Antigen Delivery to Immune Activation.Transboundary and emerging diseases · 2025Review
180 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies of lactic acid bacteria (LAB) as delivery vehicles have focused mainly on the development of mucosal vaccines, with much effort being devoted to the generation of genetic tools for antigen expression in different bacterial locations. Subsequently, interleukins have been co-expressed with antigens in LAB to enhance the immune response that is raised against the antigen. LAB have also been used as a delivery system for a range of molecules that have different applications, including anti-infectives, therapies for allergic diseases and therapies for gastrointestinal diseases. Now that the first human trial with a Lactococcus strain that expresses recombinant interleukin-10 has been completed, we discuss what we have learnt, what we do not yet understand and what the future holds for therapy and prophylaxis with LAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.